Trial Profile
To investigate metastatic castration resistant prostate cancer patients treated with Abiraterone and/or Abiraterone and Enzalutamide associated with development of liver metastases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 03 Apr 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium